Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg ( DrugBank: Estradiol, Norgestimate, Ethinyl estradiol )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 299 | Cystic fibrosis | 1 |
299. Cystic fibrosis
Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02144246 (ClinicalTrials.gov) | May 2014 | 19/5/2014 | Contraceptive Hormones and Women With Cystic Fibrosis | Contraceptive Hormones and Women With Cystic Fibrosis: Satisfaction and Effects on Disease | Cystic Fibrosis Exacerbations While on and Off Hormonal Contraception | Other: Non-hormonal period;Drug: Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg | University of Pennsylvania | Society of Family Planning | Terminated | 18 Years | 40 Years | Female | 5 | Phase 1 | United States |